Missing: Origin BioMed's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Origin BioMed's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Origin BioMed
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Origin BioMed is included in 2 Expert Collections, including Diabetes.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Latest Origin BioMed News
Aug 1, 2013
Sep 1, 2011 One of Nova Scotia's innovative life sciences companies is gearing up for future growth with support from the province and other investors. The province, through Nova Scotia Business Inc.(NSBI) Venture Capital, is providing Origin BioMed with an $850,000 follow-on investment. Avrio Ventures and GrowthWorks Atlantic are also providing financing of $650,000 and $500,000 respectively. NSBI Venture Capital has provided equity financing to help the company strengthen its financial base as it implements a new growth plan. A follow-on investment is additional financing as a company continues to grow. "The investment reflects the province's commitment to fostering innovation and helping businesses become more globally competitive," said John MacDonell, acting Minister of Economic and Rural Development and Tourism. "It aligns with Nova Scotia's jobsHere plan to create good jobs and grow a sustainable economy. " Origin BioMed is a leading innovator of over-the-counter topical drug products, which are items applied to the body surface. The Halifax company's lead product is Neuragen, which helps relieve pain caused by diabetic neuropathy, a breakdown of nerves. The original Neuragen Oil has been successful in Canada and the United States. The U.S. launch of Neuragen Cream this fall is expected to build on that success. "NSBI is working with Origin BioMed to help the company as it prepares to implement its new, strategic business plan and seek future growth," said Stephen Lund, president and CEO of NSBI. The company's products are sold in more than 40,000 stores across Canada and the United States with plans to expand. "We are proud of our current success with the Neuragen product and feel Nova Scotia has the right infrastructure and skilled workers from which to grow and meet our emerging global market opportunities," said Robert Dingee, CEO, Origin BioMed. Origin BioMed Inc. is an innovative over-the-counter consumer health products company focused on pain management. Its products are in all major drug store chains across North America. Nova Scotia Business Inc. is the province's private-sector-led business development agency. Through trade development, investment attraction, business financing and venture capital, NSBI helps local companies and attracts international businesses to Nova Scotia. NSBI Venture Capital is a mid- to late-stage investment fund focusing on Nova Scotia businesses in information and communications technology, defence and aerospace, energy, advanced manufacturing, and life sciences. Media Contact:
Origin BioMed Frequently Asked Questions (FAQ)
When was Origin BioMed founded?
Origin BioMed was founded in 2001.
Where is Origin BioMed's headquarters?
Origin BioMed's headquarters is located at 5162 Duke Street, Halifax.
What is Origin BioMed's latest funding round?
Origin BioMed's latest funding round is Unattributed VC.
How much did Origin BioMed raise?
Origin BioMed raised a total of $8.3M.
Who are the investors of Origin BioMed?
Investors of Origin BioMed include NSBI Venture Capital, GrowthWorks, Rio Investment Partners, Atlantic Canada Opportunities Agency, First Angel Network and 3 more.
Who are Origin BioMed's competitors?
Competitors of Origin BioMed include La Jolla Pharmaceutical Company, Fujirebio, Molmed, Altimmune, DermTech International and 11 more.
Compare Origin BioMed to Competitors
Efficas is a biotechnology company focused on the discovery and rapid development of nutritional bioactives with clinically-proven efficacy for the management of human and animal health. Efficas' lead product will be a product derived from an edible fruit to assist in the control of atopic dermatitis.
Eppendorf is a biotech company that develops, produces, and distributes products, services, and systems for use in life-science research laboratories worldwide. The company's product range includes pipettes, dispensers, and centrifuges as well as consumables such as micro test tubes and pipette tips. In addition, the company provides instruments and systems for cell manipulation, automated devices for liquid handling, complete equipment for DNA amplification, and biochips.
Vybion is a developer and manufacturer of recombinant proteins for therapeutic and diagnostic applications. It uses its technologies along with a highly skilled staff to develop therapeutics, vaccines, diagnostics and bioavailability for pharmaceutical and biotechnology companies.
Akron Biotechnology provides its customers with quality raw materials and components for research and development. As a scientific product supplier, the company specializes in manufacturing and supplying chemicals, biochemicals, cell culture, and cell biology products aimed at the biopharmaceutical and biotechnology markets.
Traxion Therapeutics Inc. is a biotech company focused on the development of drugs for the treatment of intractable pain, specifically neuropathic pain. Traxion has assembled a portfolio of small molecule products to address this market opportunity. These products use more selective, mechanism-based approaches which exploit recent scientific discoveries in order to develop what Traxion believes are more effective, better tolerated treatments for neuropathic pain.
Pi Proteomics LLC manufactures custom and catalog peptides for academia, the biotechnology industry, antibody companies and the pharma industry.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.